Jens-Uwe Peters 
Polypharmacology in Drug Discovery 

An essential outline of the main facets of polypharmacology in
drug discovery research

Extending drug discovery opportunities beyond the ‘one drug, one
target’ philosophy, a polypharmacological approach to the treatment
of complex diseases is emerging as a hot topic in both industry and
academic research. Polypharmacology in Drug Discovery presents an
overview of the various facets of polypharmacology and how it can
be applied as an innovative concept for developing medicines for
treating bacterial infections, epilepsy, cancer, psychiatric
disorders, and more. Filled with a collection of instructive case
studies that reinforce the material and illuminate the subject,
this practical guide:

* Covers the two-sided nature of polypharmacology–its
contribution to adverse drug reactions and its benefit in certain
therapeutic drug classes

* Addresses the important topic of polypharmacology in drug
discovery, a subject that has not been thoroughly covered outside
of scattered journal articles

* Overviews state-of-the-art approaches and developments to help
readers understand concepts and issues related to
polypharmacology

* Fosters interdisciplinary drug discovery research by embracing
computational, synthetic, in vitro and in vivo pharmacological and
clinical aspects of polypharmacology

A clear road map for helping readers successfully navigate
around the problems involved with promiscuous ligands and targets,
Polypharmacology in Drug Discovery provides real examples, in-depth
explanations and discussions, and detailed reviews and opinions to
spark inspiration for new drug discovery projects.

About the author

Jens-Uwe Peters, Ph D, works in the Medicinal Chemistry
Department at F. Hoffmann-La Roche. In his ten years at Roche, he
has been involved in numerous drug discovery projects, has
contributed to Early Safety Profiling initiatives, and has
researched opportunities for polypharmacological drug discovery.
Dr. Peters is author or coauthor on twenty-six journal papers and
is named on twenty-two patents.